These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25057941)

  • 1. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
    Stabile LP; Rothstein ME; Gubish CT; Cunningham DE; Lee N; Siegfried JM
    J Thorac Oncol; 2014 Sep; 9(9):1285-93. PubMed ID: 25057941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Queiroz de Oliveira PE; Stabile LP
    Mol Pharmacol; 2007 Sep; 72(3):769-79. PubMed ID: 17550984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
    Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
    Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.
    Stabile LP; Lyker JS; Land SR; Dacic S; Zamboni BA; Siegfried JM
    Carcinogenesis; 2006 Aug; 27(8):1547-55. PubMed ID: 16513678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
    Stabile LP; Rothstein ME; Keohavong P; Jin J; Yin J; Land SR; Dacic S; Luong TM; Kim KJ; Dulak AM; Siegfried JM
    Mol Cancer Ther; 2008 Jul; 7(7):1913-22. PubMed ID: 18645002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
    Dohadwala M; Yang SC; Luo J; Sharma S; Batra RK; Huang M; Lin Y; Goodglick L; Krysan K; Fishbein MC; Hong L; Lai C; Cameron RB; Gemmill RM; Drabkin HA; Dubinett SM
    Cancer Res; 2006 May; 66(10):5338-45. PubMed ID: 16707460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
    Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
    J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
    Xuan Y; Wang J; Ban L; Lu JJ; Yi C; Li Z; Yu W; Li M; Xu T; Yang W; Tang Z; Tang R; Xiao X; Meng S; Chen Y; Liu Q; Huang W; Guo W; Cui X; Deng W
    Mol Oncol; 2016 Apr; 10(4):610-24. PubMed ID: 26774881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
    Zhao Y; Sun Y; Zhang H; Liu X; Du W; Li Y; Zhang J; Chen L; Jiang C
    Int J Clin Exp Pathol; 2015; 8(4):3719-26. PubMed ID: 26097553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
    Ogunwobi OO; Liu C
    Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
    Shen Y; Chen Q; Li L
    Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
    Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
    Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation 
in NSCLC Development].
    Zhao J; Zhu Q; Zhang Y; Li G; Zhang Y; Li F; Bian L
    Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):245-256. PubMed ID: 38769827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N; Li H; Su F; Li J; Ma X; Gong P
    Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [c-Met and HGF expression in non-small-cell lung carcinomas].
    Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
    Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.